Abbott's FreeStyle Libre 3 Plus Now Covered Across Canada

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

Should Abbott’s AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors?

In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S.
abc7NY

4.2M FreeStyle Libre glucose monitors recalled by FDA for risk of overheating, fire

At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...
Fierce Biotech

Abbott launches AI-based Libre Assist, its new in-app feature for meal planning

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...
Monthly Prescribing Reference

FDA Approves FreeStyle Libre 14 Day Flash Glucose Monitoring System

The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear. Abbott announced that ...